Toxicity of trastuzumab labeled 177Lu on MCF7 and SKBr3 cell lines.

In this study, we labeled trastuzumab with (177)Lu to synthesize a new radiopharmaceutical for therapy of breast cancer and at the first stage investigated its therapeutic effects on SKBr3 and MCF7 breast cancer cell lines. Trastuzumab-(177)Lu showed very good in-vitro characteristics such as high radiochemical purity (91+/-0.9%), good stability in PBS buffer (86+/-2.3%) and blood serum (81+/-2.7%) up to 96 h, appropriate immunoreactivity (85.4+/-1.1%) and high cytotoxicity in HER2 expression cells. 5 fold increase in toxicity of trastuzumab-(177)Lu was observed when compared with unlabeled trastuzumab on SKBr3 cells.

[1]  Tristan Barrett,et al.  In vivo molecular imaging to diagnose and subtype tumors through receptor-targeted optically labeled monoclonal antibodies. , 2007, Neoplasia.

[2]  M. Mottolese,et al.  HER-2-positive metastatic breast cancer: trastuzumab and beyond. , 2008, Expert opinion on pharmacotherapy.

[3]  K. Ang,et al.  Sensitization of breast cancer cells to radiation by trastuzumab. , 2003, Molecular cancer therapeutics.

[4]  H. Rajabi,et al.  Radiolabeling of trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer. , 2009, Nuclear medicine and biology.

[5]  D. Scheinberg,et al.  Targeted actinium-225 in vivo generators for therapy of ovarian cancer. , 2003, Cancer research.

[6]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[7]  Aisha Siddiqa,et al.  Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways , 2008, BMC Cancer.

[8]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[9]  D. Bigner,et al.  Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands. , 2007, Nuclear medicine and biology.

[10]  R. Reilly,et al.  111In-Labeled Trastuzumab (Herceptin) Modified with Nuclear Localization Sequences (NLS): An Auger Electron-Emitting Radiotherapeutic Agent for HER2/neu-Amplified Breast Cancer , 2007, Journal of Nuclear Medicine.

[11]  C. Hudis,et al.  Cardiac dysfunction in the trastuzumab clinical trials experience. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Kai-ling Huang,et al.  The experimental study on the radioimmunotherapy of the nasopharyngeal carcinoma overexpressing HER2/neu in nude mice model with intratumoral injection of 188Re-herceptin. , 2005, Nuclear medicine and biology.

[13]  S. Jurisson,et al.  Preparation and biological evaluation of 111In-, 177Lu- and 90Y-labeled DOTA analogues conjugated to B72.3. , 2007, Nuclear medicine and biology.

[14]  M. Brechbiel,et al.  Development of a spectroscopic assay for bifunctional ligand-protein conjugates based on copper. , 2004, Nuclear medicine and biology.